-
NMPA Announcement on the Revision of the Package Insert of Somatostatin for Injection
2021-06-24
The NMPA decided to modify the items of [Adverse reactions],[Precautions] and [Drug Interactions] in the package inserts of somatostatin for injection.
-
NMPA Announcement on the Revision of the Package Insert of the Oxiracetam Preparations
2021-06-24
The NMPA decided to modify the items of [Adverse reactions], [Contraindications] and [Precautions] in the package inserts of oxiracetam preparations. On June 22, relevant issues are hereby announced as follows.
-
Announcement of NMPA and General Administration of Customs on the Establishment of Changchun Airport as a Drug Import Port
2021-06-15
According to the Drug Administration Law of the People's Republic of China, upon approval of the State Council, NMPA and General Administration of Customs agree to establish Changchun Airport as a drug import port.
-
NMPA Announcement on Adding the Medication Information for Children to the Package Inserts of Haloperidol Tablets and Other Varieties
2021-05-31
In order to better meet the clinical medication needs of children, upon the study and demonstration, package inserts of Haloperidol Tablets and other varieties may be added with the children users and dosage and usage for children according to the requirements.
-
NMPA Announcement on Implementing Relevant Matters of the Regulations for the Supervision and Administration of Medical Devices
2021-05-31
The revised Regulations for the Supervision and Administration of Medical Devices will be implemented as of June 1, 2021.
-
NMPA Announcement on the Cancellation of Registration Certificates for 283 Drugs including Megestrol Acetate Dispersible Tablets
2021-05-24
According to the Regulations for the Implementation of the Drug Administration Law of the People's Republic of China and the Provisions for Drug Registration, NMPA has decided to cancel the registration certificate of 283 drugs including Megestrol Acetate Dispersible Tablets.